Evaluating clinical trial data: Outcome measures

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 9, 2001, Pages 23-28

  Conley, Robert R ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

CLINICAL TRIAL; HEALTH CARE COST; HOSPITALIZATION; HUMAN; OUTCOMES RESEARCH; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; EVALUATION STUDIES; HEALTH STATUS INDICATORS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0034997789     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
2. Conley RR, Mahmoud R, and the Risperidone Study Group. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. Presented at the 38th annual meeting of the American College of Neuropsychopharmacology; Dec 12-16, 1999; Acapulco, Mexico
3. Ho B-C, Miller D, Nopoulos P, et al. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999;60:658-663
4. Mullen J, Reinstein M, Bari M, et al. Quetiapine and risperidone in outpatients with psychotic disorders: results of the QUEST Trial. Presented at the biennial meeting of the International Congress on Schizophrenia Research; April 17-21, 1999; Santa Fe, NM
5. Conley RR, Love RC, Kelly DL, et al. A comparison of rehospitalization rates between patients treated with atypical antipsychotics and those treated with depot antipsychotics. Presented at the 54th annual convention and scientific program of the Society of Biological Psychiatry; May 13-15, 1999; Washington, DC
6. Lang TA, Secic M. Assessing time-to-an-event as an endpoint: reporting survival analyses. In: How to Report Statistics in Medicine: Annotated Guidelines for Authors, Editors, and Reviewers. Philadelphia, Pa: American College of Physicians; 1997:137
7. Heinrichs DW, Hanlon TE, Carpenter WTJ. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-398
8. Andreasen N, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing psychopathology and diagnosis. Arch Gen Psychiatry 1993;49:615-623
9. Mintzer JE, Yeung PP, Mullen JA, et al. EPS variations in the elderly. In: New Research Abstracts of the 153rd Annual Meeting of the American Psychiatric Association; May 18, 2000; Chicago, II. Abstract NR663:236
10. Eisen SV, Dickey B, Sederer LI. A self-report symptom and problem rating scale to increase inpatients' involvement in treatment. Psychiatr Serv 2000;51:349-353